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Abstract
Two similar strains of a coryneform bacterium were isolated from human clinical material. Both strains were resistant to
vancomycin but susceptible to teicoplanin. Detailed biochemical, chemotaxonomical, and molecular genetic investigations
revealed that both isolates were members of a hitherto undescribed species of the genus Aureobacterium. The name
Aureobacterium resistens sp. nov. is proposed for the new bacterium and the type strain is CCUG 38312.
ß 1998 Federation of European Microbiological Societies. Published by Elsevier Science B.V.
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1. Introduction
In recent years, clinical microbiologists have be-
come more aware both of the clinical signi¢cance
as well as of the enormous diversity within the group
of coryneform bacteria [1]. Strains belonging to gen-
era which were previously only relevant to environ-
mental microbiologists were also shown to occur in
human clinical specimens [1]. One of these medically
relevant genera is the genus Aureobacterium, mem-
bers of which had been for many years mistakingly
included in the ‘Corynebacterium aquaticum’ group
of bacteria [2]. In 1996, Saweljew et al. reported a
fatal systemic infection with an Aureobacterium sp.
‘Mainz’ in an immunocompetent patient [3]. Nolte et
al. [4] presented the ¢rst report from the U.S. of a
lethal bacteremia due to a vancomycin-resistant, tei-
coplanin-susceptible Aureobacterium species. Inde-
pendently, a second Aureobacterium strain with the
same antimicrobial susceptibility pattern had been
isolated in Europe. The present report deals with
the comprehensive characterization, both phenotypic
and phylogenetic, of these latter two unusual strains
of coryneform bacteria, resulting in the description
of a new Aureobacterium, Aureobacterium resistens
sp. nov.
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2. Materials and methods
2.1. Microorganisms and cultivation
Aureobacterium sp. strain DMMZ 1589 (Culture
Collection University of Goºteborg, Sweden
[CCUG] 38311) was isolated in 1995 in Atlanta
from a blood culture of a 39 year-old male with
acute myelogenous leukemia [4]. Aureobacterium sp.
strain DMMZ 1710 (CCUG 38312) had been iso-
lated in 1995 in Zuºrich from a corneal ulcer of a
14 year-old female wearing contact lenses. Both
strains were subcultured on Columbia agar supple-
mented with 5% sheep blood (SBA) for 24 h in a 5%
CO2-enriched atmosphere and from these plates cells
were taken for further testing.
2.2. Phenotypical analysis
The biochemical pro¢les of strains DMMZ 1589
and DMMZ 1710 were determined as described pre-
viously [5]. Hydrolysis of tyrosine, casein, and starch
were tested according to Nash and Krenz [6]. Car-
bohydrate utilization patterns were tested in the API
50CH gallery (bioMeŁrieux, Marcy l’Etoile, France)
[7]. Chemotaxonomic investigations included deter-
mination of cellular fatty acids (CFAs) and detailed
peptidoglycan structural analysis [2]. The antimicro-
bial susceptibility patterns of both strains were ana-
lyzed with the MCN system (Merlin Diagnostics,
Bornheim, Germany) [8] and minimal inhibitory con-
centrations (MICs in Wg/ml) for vancomycin and tei-
coplanin were also independently determined on
Mueller-Hinton agar plates supplemented with 5%
sheep blood applying E-test strips (AB Biodisk, Sol-
na, Sweden).
2.3. Phylogenetic analysis
Determination of the 16S rRNA gene sequence of
strain DMMZ 1710 (EMBL accession number
Y14699) and DMMZ 1589 was by PCR-mediated
ampli¢cation of the gene followed by cycle sequenc-
ing of the PCR product, and electrophoretic analysis
using an Applied Biosystems 373A automatic se-
quencer (Foster City, USA) as described previously
[9]. Phylogenetic analysis including sequence align-
ment, calculation of percentage sequence similarity,
construction of a phylogenetic tree, and an assess-
ment of the tree topology by bootstrap analysis has
also been outlined previously [9].
3. Results and discussion
Colonies of both Aureobacterium strains DMMZ
1589 and DMMZ 1710 were up to 1.5 mm in diam-
eter after 24 h incubation, glistening, convex, of
creamy consistency, and started to develop a bright
yellow pigment. Gram stains showed short (i.e. less
than 2 Wm in length) and slim Gram-positive rods
which were arranged as single cells or in clusters.
The basic biochemical screening reactions [1] were
as follows: catalase positive; non-motile; oxidative
metabolism; nitrate reduction negative; urea hydrol-
ysis negative; esculin hydrolysis positive; acid pro-
duction from glucose, maltose, and sucrose but not
from mannitol, and xylose; CAMP reaction (see [1]
for test performance) negative. In addition, DNase
activity was observed after 2 days, tyrosine hydroly-
sis also became positive after 2 days whereas hydrol-
ysis of casein became positive after 10 days only, and
starch hydrolysis was negative. When applying the
commercial API Coryne system (bioMeŁrieux) [10]
we observed the numerical code 2472325 (a seven
digit code corresponding to 21 biochemical reac-
tions) for both strains.
Most interestingly, both strains were found to
have a vancomycin MIC of 64 indicating resistance
according to NCCLS guidelines but a teicoplanin
MIC of 2 indicating susceptibility [11]. Both results
were con¢rmed by the E-test showing a vancomycin
MIC of 48 and of 1.5 for teicoplanin. Resistance of
this type has not been reported before for any other
coryneform bacterium. In Gram-positive cocci, En-
terococcus spp. may harbour the vanB gene showing
a similar glycopeptide resistance pattern [12]. How-
ever, the vanB gene could not be detected in strain
DMMZ 1589 [4].
Chemotaxonomic investigations revealed C15:0ai
(20^23% of total CFAs), C16:0i (19^21%), and
C17:0ai (47^52%) as the predominant CFAs. Small-
er amounts of C15:0 (1^2%), C16:0 (3^4%), C17:0i
(2%), and C18:0i (1%) were also detected. Ornithine
was found to be the diamino acid of the cell wall
peptidoglycan, and its acyl type was of the glycolyl
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type. All these ¢ndings were compatible only with an
assignment of the two strains to the genus Aureobac-
terium [13]. Detailed peptidoglycan analysis revealed
that apart from D-ornithine huge amounts of L-orni-
thine were present and that both strains belonged to
the peptidoglycan type B2K ([L-ornithine]D-glutamic
acid-D-ornithine). Within the genus Aureobacterium,
A. keratanolyticum is presently the only species ex-
hibiting this unusual peptidoglycan type [14]. How-
ever, our two strains were di¡erent from the only
one A. keratanolyticum strain described in the liter-
ature [14] by their ability to hydrolyse esculin and
their acid production from glucose, maltose, and su-
crose. These data clearly indicated that strains
DMMZ 1589 and DMMZ 1710 represent a new
Aureobacterium species.
In order to investigate the phylogenetic placement
of the two clinical strains the genes encoding their
16S rRNAs were ampli¢ed by PCR and subjected to
sequence analysis. The almost complete 16S rRNA
gene sequences (approximately 1420 bp) of both
strains were determined and found to be identical
(100% sequence similarity), thereby demonstrating
that both strains belonged to the same species. Pair-
wise and treeing analyses revealed A. testaceum as
the closest (98.7% sequence similarity) phylogenetic
neighbour of the clinical strains (Fig. 1). A. kerata-
nolyticum, despite exhibiting a similar peptidoglycan
type to that of the human isolates, was somewhat
more distantly related (98.2% sequence similarity).
Considering the high 16S rDNA homologies
(s 97.6%) within the genus Aureobacterium [15,16]
it is evident that the two strains represent a new
Aureobacterium species for which the designation
Aureobacterium resistens is proposed. The precise
molecular mechanism conferring vancomycin resist-
ance while the strains remained susceptible to teico-
planin is currently under investigation.
3.1. Description of Aureobacterium resistens sp. nov.
Aureobacterium resistens (re’sis.tens. L. pres. part.
resistens, being resistant, referring to the vancomycin
resistance which is very unusual for coryneform bac-
FEMSLE 7934 5-1-98
Fig. 1. Unrooted tree showing the phylogenetic position of A. resistens within other high G+C content actinomycetes. The tree con-
structed using the neighbor-joining method was based on a comparison of approximately 1330 nucleotides of 16S rRNA genes. Bootstrap
values, expressed as a percentage of 250 replications, are given at the branching points. Numbers in brackets are EMBL/GenBank acces-
sion numbers.
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teria) cells are Gram-positive, asporogenous, small (1
to 2 Wm in length) and slim rods which are non-
motile. Colonies are up to 1.5 mm in diameter after
24 h incubation, glistening, convex, of creamy con-
sistency, and exhibit a yellow pigment. Catalase pos-
itive. Acid is produced oxidatively from glucose,
maltose, and sucrose but not from mannitol and xy-
lose. The following carbohydrates are utilized: glyc-
erol, ribose, galactose, D-fructose, D-mannose, rham-
nose, N-acetyl-glucosamine, amygdaline, salicine,
cellobiose, lactose, trehalose, xylitol, D-turanose, D-
lyxose, gluconate, 2-keto-gluconate, and 5-keto-gluc-
onate. The following carbohydrates are not utilized:
erythritol, L-arabinose, adonitol, L-methyl-xyloside,
L-sorbose, dulcitol, sorbitol, K-methyl-D-mannoside,
K-methyl-D-glucoside, melibiose, inulin, melezitose,
D-ra⁄nose, amidon, glycogen, D-fucose, D-arabitol,
and L-arabitol. Nitrate is not reduced. Esculin, tyro-
sine, and casein are hydrolyzed but not urea or
starch. The CAMP reaction is negative. DNase ac-
tivity is present. Activities of pyrazinamidase, ester-
ase (C4), esterase lipase (C8), leucine arylamidase,
cystine arylamidase, acid phosphatase, phosphoami-
dase, L-galactosidase, K-glucosidase, L-glucosidase,
N-acetyl-glucosaminidase, K-mannosidase, and K-fu-
cosidase are present whereas activities of pyrrolidon-
yl arylmidase, chymotrypsin, K-galactosidase, and L-
glucuronidase are not observed.
The cell wall contains ornithine as diamino acid,
the peptidoglycan type is B2K ([L-ornithine]D-gluta-
mic acid-D-ornithine), and of the glycolyl type.
C15:0ai, C16:0i, and C17:0ai are the predominant
cellular fatty acids. Strains are resistant to vancomy-
cin but susceptible to teicoplanin. Isolated from hu-
man clinical specimens. The type strain DMMZ 1710
has been deposited in the culture collection of the
University of Goºteborg, Sweden, as strain CCUG
38312.
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